SRR934926
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 12.450722733245728
- age_years
- 43
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.622
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.602
- IL6_JAK_STAT3_SIGNALING+0.580
- ANGIOGENESIS+0.524
- UNFOLDED_PROTEIN_RESPONSE+0.503
- MYC_TARGETS_V2+0.479
- INFLAMMATORY_RESPONSE+0.475
- INTERFERON_GAMMA_RESPONSE+0.475
- PROTEIN_SECRETION+0.461
- G2M_CHECKPOINT+0.448
Top 10 suppressed
- KRAS_SIGNALING_DN-0.436
- SPERMATOGENESIS-0.337
- PANCREAS_BETA_CELLS-0.296
- MYOGENESIS-0.109
- BILE_ACID_METABOLISM-0.028
- HEME_METABOLISM-0.024
- WNT_BETA_CATENIN_SIGNALING-0.016
- PEROXISOME+0.004
- APICAL_SURFACE+0.006
- FATTY_ACID_METABOLISM+0.012
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934913 | — | — | 0.982 |
| 2 | SRR934965 | — | — | 0.982 |
| 3 | SRR934875 | — | — | 0.979 |
| 4 | SRR934932 | — | — | 0.977 |
| 5 | SRR934837 | — | — | 0.977 |
| 6 | 113D7756-712E-4EB4-9993-BBAF3C41AFEF | — | — | 0.976 |
| 7 | SRR934747 | — | — | 0.975 |
| 8 | E9FC1686-028B-476C-B51B-4956213D874B | — | — | 0.974 |
| 9 | C9EE359E-2F42-4D20-880D-FBF8B4953731 | — | — | 0.973 |
| 10 | SRR934829 | — | — | 0.972 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.622 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.602 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.580 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.524 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.503 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.479 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.475 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.475 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.461 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.448 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.440 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.434 | Idelalisib | — uncovered |
| HYPOXIA | 0.427 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.423 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.416 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.407 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.406 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.401 | Inavolisib | — uncovered |
| COMPLEMENT | 0.398 | Inavolisib | — uncovered |
| APOPTOSIS | 0.392 | Idelalisib | — uncovered |